|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...5253545556575859606162...6768» |
- | PAT-SM6 / Patrys
New P1 trial: Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 14, 2012
P1, N=12, Completed, Sponsor: Patrys Ltd.
- lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Nov 14, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting
- | Promacta (eltrombopag) / Novartis
Enrollment closed: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2012
P2, N=12, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Ca-Art-PXE: Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=71, Completed, Sponsor: University Hospital, Angers
Recruiting --> Active, not recruiting Recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial withdrawal: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Nov 13, 2012
P1/2, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed Completed --> Withdrawn
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial initiation date: Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2012
P3, N=312, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Withdrawn Initiation date: Apr 1994 --> Jul 1994
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Apr 1994 --> Jul 1994 N=41 --> 23
- Rituxan (rituximab) / Roche
Enrollment change: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Nov 13, 2012
P1/2, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
N=41 --> 23 N=12 --> 0
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=12 --> 0 Active, not recruiting --> Completed
- Ninlaro (ixazomib) / Takeda
Enrollment open: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 8, 2012
P1, N=24, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Zyflo (zileuton) / Chiesi
Trial termination: Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Nov 7, 2012
P1/2, N=3, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Not yet recruiting --> Recruiting Recruiting --> Terminated; insufficient enrollment
- Zyflo (zileuton) / Chiesi
Enrollment change: Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Nov 7, 2012
P1/2, N=3, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Terminated; insufficient enrollment N=12 --> 3
- Rituxan (rituximab) / Roche
Enrollment change: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 7, 2012
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
N=12 --> 3 N=24 --> 18
- Coagadex (coagulation factor X (human)) / Bio Products Laboratory (BPL)
New P3 trial: A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years (clinicaltrials.gov) - Nov 4, 2012
P3, N=16, Not yet recruiting, Sponsor: Bio Products Laboratory
- melphalan / Generic mfg.
Trial initiation date: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts (clinicaltrials.gov) - Nov 4, 2012
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
N=24 --> 18 Initiation date: Oct 2012 --> Feb 2013
- Enrollment change: Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL (clinicaltrials.gov) - Nov 4, 2012
P1, N=13, Active, not recruiting, Sponsor: Baylor College of Medicine
Initiation date: Oct 2012 --> Feb 2013 N=18 --> 13
- Trial completion: Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov) - Nov 3, 2012
P=N/A, N=190, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
N=18 --> 13 Active, not recruiting --> Completed
- staphylococcal protein A (PRTX-100) / Protalex
Trial termination: Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP (clinicaltrials.gov) - Oct 31, 2012
P1, N=9, Terminated, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed Recruiting --> Terminated; Terminated due to recruitment not meeting expectations.
- staphylococcal protein A (PRTX-100) / Protalex
Enrollment change: Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP (clinicaltrials.gov) - Oct 31, 2012
P1, N=9, Terminated, Sponsor: Protalex, Inc.
Recruiting --> Terminated; Terminated due to recruitment not meeting expectations. N=21 --> 9
- lorvotuzumab mertansine (IMGN901) / AbbVie
Enrollment closed, Combination therapy: IMGN901 in Combination With Lenalidomide and Dexamethasone (clinicaltrials.gov) - Oct 31, 2012
P1, N=50, Active, not recruiting, Sponsor: ImmunoGen, Inc.
N=21 --> 9 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg.
New P2 trial: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - Oct 30, 2012
P2, N=10, Recruiting, Sponsor: University of Utah
- Enrollment change: Autoantibody Specificity and Response to IVIG in ITP (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=200, Recruiting, Sponsor: Shandong University
Recruiting --> Active, not recruiting N=138 --> 200
- Enrollment open: Autoantibody Specificity and Response to IVIG in ITP (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=200, Recruiting, Sponsor: Shandong University
N=138 --> 200 Completed --> Recruiting
- dabigatran etexilate / Generic mfg.
Trial completion: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients (clinicaltrials.gov) - Oct 30, 2012
P1, N=10, Completed, Sponsor: Capital District Health Authority, Canada
Completed --> Recruiting Not yet recruiting --> Completed
- sorafenib / Generic mfg.
Trial completion: Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 30, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial termination: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 29, 2012
P1/2, N=73, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Trial completed prematurely.
- | PVX-410 / OncoPep
New P1/2 trial: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma (clinicaltrials.gov) - Oct 29, 2012
P1/2, N=13, Recruiting, Sponsor: OncoPep, Inc.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P1/2 trial: Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=36, Completed, Sponsor: Neufeld, Ellis J, MD, PhD
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
Completed --> Terminated; Trial completed prematurely. N=40 --> 18
- tabalumab (LY2127399) / Eli Lilly
Enrollment closed, Combination therapy: A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib (clinicaltrials.gov) - Oct 23, 2012
P1, N=50, Active, not recruiting, Sponsor: Applied Molecular Evolution
N=40 --> 18 Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial completion: Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) - Oct 23, 2012
P2, N=72, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Observational data, Enrollment change, Adverse events, Serious adverse event: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=35, Completed, Sponsor: University Hospital, Toulouse
Active, not recruiting --> Completed N=50 --> 35
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Observational data, Adverse events, Serious adverse event: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=35, Completed, Sponsor: University Hospital, Toulouse
N=50 --> 35 Recruiting --> Completed
- bortezomib / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 (clinicaltrials.gov) - Oct 21, 2012
P2, N=31, Completed, Sponsor: University Hospital, Toulouse
Recruiting --> Completed Active, not recruiting --> Completed
- sirexatamab (DKN-01) / Leap Therap
New P1/2 trial: A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2012
P1/2, N=20, Recruiting, Sponsor: Dekkun Corporation
- dinaciclib (MK-7965) / Merck (MSD)
New P1 trial, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2012
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| carfilzomib / Generic mfg.
Clinical: FOCUS: A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2012
P3, N=302, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| KW 2478 / Kyowa Kirin
Enrollment closed, Combination therapy: A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2012
P1/2, N=95, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | lucatumumab (CHIR 12.12) / Novartis, Xoma
Trial completion: Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2012
P2, N=33, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Terminated --> Completed
- ||| RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment change, Surgery: FiCCS: Fibrinogen Concentrate In Children After Cardiac Surgery (clinicaltrials.gov) - Oct 16, 2012
P2, N=63, Completed, Sponsor: University of Sao Paulo
Terminated --> Completed N=80 --> 63
- |||| RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: FiCCS: Fibrinogen Concentrate In Children After Cardiac Surgery (clinicaltrials.gov) - Oct 16, 2012
P2, N=63, Completed, Sponsor: University of Sao Paulo
N=80 --> 63 Recruiting --> Completed
- Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
New P1 trial: rhFVIIa: A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (clinicaltrials.gov) - Oct 15, 2012
P1, N=15, Completed, Sponsor: rEVO Biologics
- | Recomodulin (recombinant thrombomodulin alfa) / Asahi Kasei
Enrollment open: Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment (clinicaltrials.gov) - Oct 15, 2012
P4, N=40, Recruiting, Sponsor: Asahi Kasei Pharma Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| dinaciclib (MK-7965) / Merck (MSD)
Trial completion, Metastases: Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (clinicaltrials.gov) - Oct 15, 2012
P1, N=123, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| bortezomib / Generic mfg.
New P2 trial: Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant (clinicaltrials.gov) - Oct 11, 2012
P2, N=150, Active, not recruiting, Sponsor: Mayo Clinic
- ||| bortezomib / Generic mfg.
Enrollment closed: Velcade Consolidation Bone Study (clinicaltrials.gov) - Oct 10, 2012
P2, N=106, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms (clinicaltrials.gov) - Oct 10, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P4 trial: Viral Kinetics in HCV Clearance in Subjects With Hemophilia (clinicaltrials.gov) - Oct 9, 2012
P4, N=20, Active, not recruiting, Sponsor: Kenneth Sherman
- | Recomodulin (recombinant thrombomodulin alfa) / Asahi Kasei
New P4 trial: Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment (clinicaltrials.gov) - Oct 9, 2012
P4, N=40, Recruiting, Sponsor: Asahi Kasei Pharma Corporation